These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 6994305)

  • 21. A prospective randomized double-blind controlled study of cadaver donor pretreatment with cyclophosphamide in human renal transplantation.
    Chatterjee SN; Smith R; Fine S; Schulman B; Fine RN
    Transplant Proc; 1981 Mar; 13(1 Pt 2):709-11. PubMed ID: 7022938
    [No Abstract]   [Full Text] [Related]  

  • 22. The Bergamo Kidney Transplant Program.
    Perico N; Cravedi P; Ruggenenti P; Gotti E; Rota G; Locatelli G; Gambara V; Perna A; Rota S; Remuzzi G
    Clin Transpl; 2005; ():85-100. PubMed ID: 17424727
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Developing ways of reducing allograft immunogenicity.
    Guttmann RD
    Can Med Assoc J; 1981 Jan; 124(2):143-5. PubMed ID: 7006782
    [No Abstract]   [Full Text] [Related]  

  • 24. Donor pretreatment on perfused cadaver kidneys: experimental observations.
    Sy G; Taiyebb S; Toledo-Pereyra LH
    Am Surg; 1981 Jul; 47(7):307-8. PubMed ID: 7020513
    [No Abstract]   [Full Text] [Related]  

  • 25. Role of donor age and acute rejection episodes on long-term graft survival in cadaveric kidney transplantations.
    Emiroğlu R; Yagmurdur MC; Karakayali F; Haberal C; Ozcelik U; Colak T; Haberal M
    Transplant Proc; 2005 Sep; 37(7):2954-6. PubMed ID: 16213272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prolongation of kidney allograft survival in dogs with donor pretreatment.
    Chassot PG; Beaudoin JG; Guttmann RD
    Surg Forum; 1974; 25(0):314-6. PubMed ID: 4612787
    [No Abstract]   [Full Text] [Related]  

  • 27. The LifeLink Foundation and cadaver kidney transplantation in Tampa.
    LeFor WM; Wright CE; Bowers VD; Heinrichs DF; Shires DL
    Clin Transpl; 1999; ():149-58. PubMed ID: 11038633
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors influencing outcome of kidney allografts from pretreated cadaveric donors.
    Sterioff S; Zincke H; Waltzer WC; Moore SB; Frohnert PP; Offord KP
    Arch Surg; 1981 Jan; 116(1):73-7. PubMed ID: 7008743
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Major effects of delayed graft function and cold ischaemia time on renal allograft survival.
    Quiroga I; McShane P; Koo DD; Gray D; Friend PJ; Fuggle S; Darby C
    Nephrol Dial Transplant; 2006 Jun; 21(6):1689-96. PubMed ID: 16490743
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Organ Procurement Organization and transplant center effects on cadaver renal transplant outcomes.
    Cho YW; Cecka JM
    Clin Transpl; 1996; ():427-41. PubMed ID: 9286586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term results with elective cyclosporine withdrawal at three months after renal transplantation--appropriate for living-related transplants.
    Kahn D; Ovnat A; Pontin AR; Swanepoel CR; Cassidy MJ
    Transplantation; 1994 Dec; 58(12):1410-2. PubMed ID: 7809935
    [No Abstract]   [Full Text] [Related]  

  • 32. Donor age and graft outcome in cadaver renal transplantation.
    Kumar MS; Stephan R; Chui J; Chvala RP; Brezin J; Katz SM; Abouna GM
    Transplant Proc; 1993 Dec; 25(6):3097-8. PubMed ID: 8266467
    [No Abstract]   [Full Text] [Related]  

  • 33. Pediatric renal transplantation in a single center from Brazil.
    Abbud-Filho M; Ramalho H; Barberato JB; Silva ML; Yamazaki W; Salgueiro MC; Zerati-Fo M; D'Avila CL; Bezas AG
    Transplant Proc; 1995 Apr; 27(2):1834. PubMed ID: 7725526
    [No Abstract]   [Full Text] [Related]  

  • 34. Effect of immunologic donor pretreatment on survival of perfused canine renal allografts.
    Pechan W; Novick AC; Stowe N; Magnusson M; Straffon RA
    Invest Urol; 1980 Jul; 18(1):74-6. PubMed ID: 6997225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Variable cyclosporine exposure: a risk factor for chronic allograft nephropathy and graft loss?
    He X; Johnston A
    Transplant Proc; 2004 Jun; 36(5):1321-6. PubMed ID: 15251323
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Donor pretreatment with cyclophosphamide and methylprednisolone.
    Brom HL; van Breda Vriesman PJ
    Transplantation; 1983 Jul; 36(1):106-7. PubMed ID: 6408773
    [No Abstract]   [Full Text] [Related]  

  • 37. Significance of the donor age effect on kidney transplants.
    Terasaki PI; Gjertson DW; Cecka JM; Takemoto S; Cho YW
    Clin Transplant; 1997 Oct; 11(5 Pt 1):366-72. PubMed ID: 9361925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcome of cadaver kidneys using nonideal donors.
    Madden RL; Munda R; Hariharan S; Alexander JW; First MR
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1568-9. PubMed ID: 8442193
    [No Abstract]   [Full Text] [Related]  

  • 39. [Improvement of the results of renal transplantation by the use of antilymphocyte globulin (ALG)].
    Renna E; Alfani D; Monari C; Trovati A; Berloco P; Famulari A; Cucchiara G; Cortesini R
    Minerva Chir; 1980 May; 35(10):747-50. PubMed ID: 7005730
    [No Abstract]   [Full Text] [Related]  

  • 40. Influence of original disease on long-term outcome of cadaver kidney transplant. Collaborative Transplant Study.
    Opelz G
    Transplant Proc; 1996 Jun; 28(3):1148-9. PubMed ID: 8658603
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.